Radiopharmaceutical trials introduce a uniquely unforgiving clock. For this PSMA-targeted prostate cancer imaging study, investigational product had to be administered within two hours of delivery. From dosimetry to scanner calibration, every detail had to be executed with speed, accuracy, and repeatability.
Indication |
Prostate Cancer (Imaging Study, PSMA-targeted) |
Trial Phase |
Phase 3, Imaging (non-interventional) |
Population |
Men with prostate cancer, many in “watch and wait” cohorts |
Geography |
United States and Canada |
Study Duration |
Multi-year, expanded enrollment |
Sites Activated |
10+ initially, expanded after success |
Challenge |
Radiologic constraints, infrastructure licensing, delivery timing for IP |
The sponsor initially anticipated modest enrollment and limited geographic reach. But early results—and an abundant “watch and wait” patient population—suggested the trial could scale. That brought new pressures: Could the system hold under a heavier load? Could sites be vetted and activated fast enough to avoid bottlenecks? Could radiologic material be administered safely and compliantly at scale?
Success depended not just on infrastructure but on relationships—with nuclear medicine teams, imaging vendors, local pharmacies, and regulators.
Precision’s feasibility process focused on identifying sites with nuclear medicine expertise and radiopharmaceutical access—departments often siloed in traditional workflows. Each selected site needed:
Sites also needed a track record of patient volume and an understanding of how to care for radiolabeled patients during and after administration.
With IP half-life measured in hours, logistics had to be airtight. A dedicated Logistics Coordinator oversaw:
This approach ensured no patient was ever dosed late, and no product expired in transit.
Site startup required multiple levels of regulatory clearance. Many sites needed license renewals or updates to accommodate radionuclide use for clinical trials. Precision:
Precision provided targeted training and materials to ensure safe and efficient trial execution:
CRAs were supported through documentation, training tools, and backup from PM and CTA teams—essential as many sites operated with rotating nuclear med and pharmacy staff. Investigator meetings and site-level communications reinforced protocol fidelity, and risk mitigation was proactive rather than reactive.
Radiopharmaceutical imaging trials demand more than precision—they demand orchestration. With logistics planned down the minute level detail, multilayered compliance, and siloed clinical infrastructure, even small errors can cascade.
Precision for Medicine delivers a complete solution, integrating nuclear medicine know-how with traditional oncology expertise. Our operational structure—with dedicated logistics, feasibility mapping, and teamwide reinforcement—ensures your imaging study doesn’t just meet the mark, it exceeds expectations.